Apr 25, 2023 · While Novo Nordisk is probably the better weight-management stock, a more diverse product lineup and development pipeline make Eli Lilly the better overall …

Dec 26, 2024 · Enter Eli Lilly (LLY 2.45%) and Novo Nordisk (NVO 8.47%), the makers behind blockbuster glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro, Zepbound, Ozempic, …

Oct 16, 2024 · The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen.

Aug 3, 2024 · Eli Lilly (LLY 2.45%) and Novo Nordisk (NVO 8.47%) are the two big names dominating the anti-obesity market today. They've been generating billions in revenue from …

Nov 2, 2023 · On Thursday, Novo Nordisk, the Denmark-based company behind Ozempic and Wegovy, reported a 29% increase in sales to $8.4 billion for the third quarter. Eli Lilly, which …

Feb 16, 2024 · U.S.-based Eli Lilly and Denmark's Novo Nordisk have struck gold with their weight-loss drugs, sending their shares to stratospheric levels and putting them on par with …

Aug 8, 2023 · Shares of pharmaceutical giant Eli Lilly skyrocketed to a record high on Tuesday, after the company reported a surge in sales of its diabetes and weight loss drug Mounjaro, …

4 days ago · Compare Eli Lilly and Co LLY and Novo Nordisk NVO. Get comparison charts for tons of financial metrics!

Aug 21, 2024 · Novo Nordisk and Eli Lilly are expanding beyond obesity drugs, targeting new markets for long-term growth. Eli Lilly's stock shows stronger technical momentum, trading …

Jan 3, 2024 · Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli …